Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews @urotoday @OncoAlert

⭐️ Huge congratulations to the one & only @PGrivasMDPhD on being named 👉🏼Medical Director of International Program & Local/Regional Outreach @fredhutch ! A visionary leader living in Seattle whose impact knows no borders- & already doing amazing things - this role couldn’t be

Pitch your boldest idea. Pitch it live at #SCHD26 and compete for a $25,000 @binaytara Research Grant! Think Shark Tank for science — fast, inspiring, and real impact. Learn more here https://t.co/XVoMCrTfud

Happy Bitcoin Whitepaper Day 🧡 There’s no ceiling for Bitcoin because there’s no bottom for fiat.

@NEJM Prostate cancer screening with PSA testing prevents death due to prostate cancer . ⭐The European Randomized Study of Screening for Prostate Cancer (ERSPC) commenced in 1993 ⭐In men aged 55 -65 years, with a median follow-up of 23 years. ⭐Relative risk ⬇️ : 13%

🚀 Fantastic to see @PGrivasMDPhD launch the new Oncology Insights podcast with @fredhutch👉sharp clinical expertise & a global perspective on cancer care, trials, and education. Episode 1 is a must-watch — insightful & deeply engaging. @ASCO @BladderCancerUS @FredHutchGO

1/5 Our new @CellRepMed study delivers the largest #RenalMedullaryCarcinoma molecular profiling via @BostonGeneCorp + translational testing designed to uncover targetable vulnerabilities: https://t.co/TGksd8oLWM #MsaouelLab #endRMC #rarecancers

The award-winning documentary that Sen. Adam Schiff demanded to have removed from Amazon Prime shows how metabolic and other natural cancer treatments work. "We're not giving cancer an opportunity to detour . . . to escape down one of its usual [biochemical] pathways."

@AzadOncology @EUplatinum @LouiseKostos @PeterMacCC @neerajaiims @PGrivasMDPhD @montypal @pros_tic @urotoday @TiansterZhang @DrYukselUrun @EdmondMKwan @DrChoueiri We shouldn't t just sequence with a "standard of care" first, second, third line, etc. approach. The future is individualisation to optimise sequencing and combination therapy, with earlier response assessment and risk adapted decision making. @AzadOncology this research is an

1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum! Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA. https://t.co/koAm8SgnK9 Thanks to @LouiseKostos Heidi Fettke @PeterMacCC

What a delight to hear from Dr. Neeraj Agarwal from @huntsmancancer at our @SylvesterCancer Grand-Rounds! An exceptionally insightful session on how to personalize therapy in prostate cancer - selecting the right patient population, integrating genomics, and understanding when to

Results from the phase 3 #PSMAfore trial in metastatic castration-resistant #ProstateCancer. Karim Fizazi, MD, PhD @GustaveRoussy joins @neerajaiims @huntsmancancer discussing the results, demonstrating the primary endpoint of radiographic progression-free survival was met, with

I suspect an ADC, alone or in combination with a T cell engager, will beat docetaxel chemo in prostate cancer in thr not too distant future #uromigosLive . Here @PBarataMD tells us how and when that might happen. @Silke_Gillessen @OncoAlert @Annals_Oncology @APCCC_Lugano

#tumorboardtuesday ✅Txs4⃣#mCRC have improved significantly - but still many Pts will need additional therapies 📢Join us Tuesday, 10-28-25 at 8PM ET as @pashtoonkasi & @mariaf_teix🗣️3rd-Line Decision-Making in Non-Driver mCRC RT and bring others into the discussion‼���

Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here @scocmem described how these and other biomarkers are changing bladder cancer. @PGrivasMDPhD @OncoAlert #uromigosLive

JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1). BIG NEWS for GU Oncology + Kidney Cancer patients! https://t.co/poOKpXP5nJ https://t.co/wP9gu8ppLI

Mobile users can now win a device health check worth $279

A stellar @cityofhope Medical Oncology Grand Rounds delivered by @BradMcG04 @DanaFarber. Brilliant overview of #adjuvant tx for #kidneycancer that set the stage for his P3 @ALLIANCE_org trial comparing #pembrolizumab +/- #tivozanib.

🚨Big day for RCC: 2 positive belzutifan combo studies‼️ - Belzutifan + pembro (adjuvant): DFS ✅ - Belzutifan + lenvatinib (pretreated mx): PFS ✅ Well tolerated & promising partner but is combining better than sequencing? Will EMA need OS? @OncoAlert @OncoReporte @DrChoueiri

Powerful words from @ASTRO_org President @NehaVapiwala at #PCF @PCFnews!! Dr. Vapiwala is a strong advocate for impactful scientific research as a driver of innovation in radiation oncology. Truly grateful for her leadership of our #radonc field!!!

Just in @TheLancetOncol 👉Ph3 CYCLONE 2: Abemaciclib + abiraterone vs. abi did not improve rPFS (primary endpoint) in mCRPC #ProstateCancer. Higher-risk pts (M1 at dx, Gleason ≥8, ⬆️PSA) seem to benefit more @OncoAlert @urotoday @PCF_Science Link👉 https://t.co/bjZGCvEswM

A big thanks to all those who voted for Forever Young at @MVFilmFest. Stream the award-winning film today exclusively on Substack. Visit the link in bio to learn more.

(5/6) Most exciting part is this novel MOA has very encouraging prelim activity against mCRPC. In pts with ≥ 6 wks tx, PSA50 was 59%, PSA90 was 32%, PR in 5/5 pts with RECIST-evaluable, and activity regardless prior tx or genomic alterations

(1/6) Introducing an AR RIPTAC therapy, HLD-0915, for men with mCRPC by @HaldaTx We presented data from the FIH, phase 1 trial at the @AACR #Targets25 meeting. Here’s the Tweetorial for this active, tolerable, oral med and link to the slides https://t.co/mKbro4l0Or